Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer
…, J Mezger, M Steins, L Bosquée… - Journal of clinical …, 2014 - ascopubs.org
Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
…, L Bosquée, JM Trigo, A Spira, L Tremblay… - The lancet …, 2014 - thelancet.com
Background Effective maintenance therapies after chemoradiotherapy for lung cancer are
lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy …
lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy …
Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy
N Barthelemy-Brichant, L Bosquée, D Cataldo… - International Journal of …, 2004 - Elsevier
PURPOSE: To assess, in lung cancer patients, the effects of thoracic radiotherapy (RT) on
the concentrations of transforming growth factor-β 1 (TGF-β 1 ) and interleukin-6 (IL-6) in the …
the concentrations of transforming growth factor-β 1 (TGF-β 1 ) and interleukin-6 (IL-6) in the …
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma
…, J Thimpont, P Germonpré, L Bosquée… - American journal of …, 2010 - atsjournals.org
… SM levels ranged from undetectable to 96.32 nmol/L. Levels below the detection limit (0.30
nmol/L) were arbitrary set at 0.15 nmol/L. In patients with MPM, SM levels were significantly …
nmol/L) were arbitrary set at 0.15 nmol/L. In patients with MPM, SM levels were significantly …
[HTML][HTML] Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma
…, R Gosselin, W De Wever, L Bosquée… - Journal of Thoracic …, 2011 - Elsevier
Introduction Soluble mesothelin (SM), megakaryocyte potentiating factor (MPF), and
osteopontin (OPN) are blood biomarkers of mesothelioma. This study evaluates their use as …
osteopontin (OPN) are blood biomarkers of mesothelioma. This study evaluates their use as …
[HTML][HTML] Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stage IB to III MAGE-A3 …
…, G Fasola, V Potter, P Taylor, L Bosquee… - Journal of Thoracic …, 2015 - Elsevier
Introduction To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in
patients with stage IB–III MAGE-A3-positive non–small-cell lung cancer (NSCLC) who were or …
patients with stage IB–III MAGE-A3-positive non–small-cell lung cancer (NSCLC) who were or …
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom …
…, K Nackaerts, C Dooms, D Galdermans, L Bosquée… - Lung Cancer, 2003 - Elsevier
Background: We previously reported that treatment of patients with symptomatic advanced
non-small cell lung cancer with single agent Gemcitabine (GEM) resulted in a superior clinical…
non-small cell lung cancer with single agent Gemcitabine (GEM) resulted in a superior clinical…
[HTML][HTML] The importance of accurate lymph node staging in early and locally advanced non-small cell lung cancer: an update on available techniques
ES Kim, L Bosquée - Journal of Thoracic Oncology, 2007 - Elsevier
Medical oncologists are faced with multiple factors to consider when staging a patient with
suspected or confirmed non-small cell lung cancer (NSCLC). Identifying pathological nodal (…
suspected or confirmed non-small cell lung cancer (NSCLC). Identifying pathological nodal (…
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer
GV Scagliotti, P Germonpré, L Bosquée… - Lung cancer, 2010 - Elsevier
BACKGROUND: This is a phase II randomized study to evaluate the efficacy and safety of
bortezomib and pemetrexed alone or in combination, in patients with previously treated …
bortezomib and pemetrexed alone or in combination, in patients with previously treated …
Increased TGFβ1 plasma level in patients with lung cancer: potential mechanisms
…, JL David, L Bosquée, T Bury, L Seidel… - European journal of …, 2002 - Wiley Online Library
Background Plasma transforming growth factor β 1 (TGFβ 1 ) levels are elevated in patients
with lung cancer. As TGFβ 1 is mainly found in platelets and as nonmalignant pulmonary …
with lung cancer. As TGFβ 1 is mainly found in platelets and as nonmalignant pulmonary …